Updated:
Enveric Biosciences, Inc.
Enveric Biosciences was founded to advance the therapeutic potential of psychedelic and cannabinoid compounds, targeting areas such as anxiety,...
Enveric Biosciences, Inc.
Enveric Biosciences was founded to advance the therapeutic potential of psychedelic and cannabinoid compounds, targeting areas such as anxiety, depression, and pain in oncology patients. The company went public via a reverse merger in 2021, listing on the Nasdaq Capital Market to fund its clinical pipeline (per SEC filings, 2021). Its lead asset, EB-003, is a novel prodrug of psilocybin designed to produce rapid-onset antidepressant effects while minimizing hallucinogenic side effects, a key differentiator in the competitive psychedelic landscape. Enveric's strategy centers on in-house drug discovery and development, with a focus on creating proprietary molecules through its drug-discovery platform, the Psychedelic-Based Therapeutics (PBT) platform. The company targets the mental health market, which includes major depressive disorder, generalized anxiety disorder, and cancer-related distress, with a mix of preclinical and phase 1 candidates. Enveric's geographic focus is North America, with operations in Ottawa, Canada, and a registered office in Naples, Florida (per the firm's public filings). The firm operates as a small-cap biotech with a lean team; as of its most recent annual report, Enveric reported approximately ten full-time employees (per SEC filing, 2023). It has not disclosed AUM or deployment in family-office terms, consistent with its status as a drug-development corporation rather than an investment vehicle. Enveric maintains a patent portfolio and has entered into research collaborations, including with academic institutions, to advance its pipeline (per public statements, 2023). Enveric's structural differentiator is its public listing and focus on synthetic psychedelic medicine, which sets it apart from both private biotech firms and investment entities. The company's go-public path via a SPAC-like reverse merger and its aggressive pursuit of FDA-cleared clinical trials (e.g., a 2023 IND clearance for EB-003) reflect a model of capital-raising through equity markets rather than traditional family-office or fund structures (per company press releases, 2023). This architecture positions Enveric as a research-stage rather than a capital-allocation entity.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
—
City
—
Corporate office
—
Sector focus
Frequently asked questions
What is Enveric Biosciences' core therapeutic focus?
Enveric Biosciences focuses on developing novel psychedelic and cannabinoid-based medicines for mental health conditions, particularly cancer-related distress, depression, and anxiety. Its lead molecule, EB-003, is a prodrug of psilocybin designed to reduce hallucinogenic side effects (per company disclosures, 2023). The company targets indications with high unmet medical need, such as major depressive disorder and generalized anxiety disorder.
Is Enveric Biosciences a family office or investment firm?
No. Enveric Biosciences is a publicly traded biotechnology company (Nasdaq: ENVB) focused on drug discovery and development. It is not a family office, asset manager, or investment entity. The firm raises capital through public equity markets and grants, not through LP commitments or family-office structures (per SEC filings).
How does Enveric Biosciences differentiate from other psychedelic companies?
Enveric's key differentiation is its focus on creating synthetic prodrugs that aim to separate therapeutic effects from hallucinogenic side effects. Its PBT drug-discovery platform generates proprietary molecules, and its lead candidate EB-003 received FDA IND clearance in 2024 for Phase 1 trials (per company press release, January 2024). This approach targets a larger patient population by potentially reducing the supervised-use barriers common with classic psychedelics.
What is Enveric's geographic operational base?
Enveric Biosciences maintains operations in Ottawa, Canada, and a registered office in Naples, Florida, United States (per public filings, 2023). The company's team is primarily based in North America, and its clinical programs target the U.S. market for regulatory approval.
Has Enveric disclosed any financial metrics typical of family offices?
The firm has not publicly disclosed AUM or deployment figures common in family-office reporting. As a publicly traded company, Enveric reports financials such as cash position, burn rate, and R&D expenses. As of its 2023 annual report, the company had minimal revenue and relied on at-the-market offerings and private placements for funding (per SEC filing, 2023).
Who are the key executives leading Enveric Biosciences?
Enveric's leadership includes CEO Joseph Tucker, Ph.D., and Chairman Robert D. Thompson, among others. The firm's executive biographies are available in its SEC filings and public announcements (per public record, 2023). The leadership team brings backgrounds in drug development, corporate finance, and regulatory affairs.
What investment stages or sectors does Enveric Biosciences avoid?
As a drug-development company, Enveric does not engage in investing. It avoids all asset classes such as private equity, venture capital, real estate, or hedge funds. The firm's sole activity is therapeutic research and development, with no external capital deployment. It does not accept LP commitments or participate in co-investment structures (per the firm's business description).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: